Recent Quotes (30 days)

You have no recent quotes
chg | %

DiagnoCure Inc.  

(Public, TSE:CUR)   Watch this stock  
Find more results for CUR
-0.005 (-4.76%)
Dec 18 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.10 - 0.11
52 week 0.10 - 0.24
Open 0.11
Vol / Avg. 171,824.00/39,003.00
Mkt cap 4.30M
P/E     -
Div/yield     -
EPS -0.07
Shares 43.04M
Beta 0.15
Inst. own     -

Key stats and ratios

Q3 (Jul '14) 2013
Net profit margin -328.58% -531.40%
Operating margin -330.12% -541.76%
EBITD margin - -412.32%
Return on average assets -32.39% -37.34%
Return on average equity - -124.21%
Employees 11 -
CDP Score - -


4535 Wilfrid-Hamel Blvd Suite 250
+1-418-5276100 (Phone)
+1-418-5270240 (Fax)

Website links


DiagnoCure, Inc. ( DiagnoCure) is a Canada-based life sciences company engaged in developing and commercializing high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. The Company is focused on the development and commercialization of molecular diagnostic tests for the detection and management of cancer. The Company also focuses on the development of genomic diagnostic tests for cancer. The Company�s product includes Analyte Specific Reagent. On February 15, 2012, the Company�s PROGENSA PCA3 test was approved by Food and Drug Administration (FDA). On August 1, 2012, Gen-Probe has become a wholly-owned subsidiary of Hologic Inc., licensee of the Company, which operates under the name Hologic Gen-Probe.

Officers and directors

Yves Fradet M.D. Non-Independent Chairman of the Board, President, Chief Medical Officer
Frederic Boivin Senior Director - Finance and Administration
Vincent R. Zurawski Jr., Ph.D. Non Executive Lead Independent Director
Andrew J. Sheldon Director
Jacques Simoneau Director
Age: 56
Louise Proulx Ph.D. Non-Executive Independent Director